Samsung Biologics signs KRW 93.50 billion deal. 25 analysts buy Samsung Biologics stock

Published on 10/05/2026 at 15:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit KRW 1,320.90 billion, up 30.14 percent year over year. Samsung Biologics stock has a KRW 1.97 million target from 26 analysts.

Samsung Biologics, KR7207940008, Illustration mit AI erstellt.

Samsung Biologics (KR7207940008) signed a KRW 93.50 billion contract on October 2, 2026, while its second-quarter revenue reached KRW 1,320.90 billion. The contract runs through December 31, 2031, and the latest labor dispute adds an operational risk to the company's expansion strategy.

Contract adds long-term revenue visibility

According to Aju Press on October 2, 2026, Samsung Biologics agreed to manufacture pharmaceuticals for a European pharmaceutical company in a contract worth KRW 93.50 billion, or USD 83.50 million. The customer remains confidential, and the contract value equals 2.05 percent of the company's consolidated revenue reported at the end of fiscal year 2025.

The agreement is scheduled to run from October 2, 2026, to December 31, 2031. Its duration matters because Samsung Biologics is expanding capacity while bringing Plant 5 and the Rockville manufacturing facility into its global network.

Labor dispute tests production resilience

According to SBS on October 2, 2026, the Samsung Biologics union plans a second general strike lasting three weeks from October 26, 2026, after three post-adjustment meetings failed to produce an agreement. Management has proposed a 6.20 percent wage increase, while the union has sought a fixed increase of 15.00 percent.

Management also said the previous general strike caused KRW 150.00 billion in losses, according to SBS. That figure gives the labor dispute a direct financial dimension, especially because biopharmaceutical production can require an entire batch to be discarded when part of a process stops.

Revenue growth supports the expansion case

Samsung Biologics reported KRW 1,320.90 billion in revenue and KRW 586.40 billion in operating profit for the second quarter of 2026, according to Samsung Biologics in its July 23, 2026 results release. Revenue increased from KRW 1,014.20 billion in the second quarter of 2025, a calculated gain of 30.14 percent, while operating profit rose from KRW 477.20 billion, a calculated gain of 22.83 percent.

The company also reported first-half 2026 revenue of KRW 2,578.00 billion and operating profit of KRW 1,167.00 billion. Cumulative contract value reached USD 21.60 billion, giving the new contract a small share of a much larger order base.

Analysts see a higher valuation

Investing.com lists 26 analysts in its latest poll, with 25 Buy ratings, one Hold rating and no Sell ratings. The average 12-month target is KRW 1,971,805, which rounds to KRW 1.97 million, while HSBC initiated coverage with a KRW 2.10 million target on September 21, 2026.

The combination of contract growth and rising manufacturing capacity supports the long-term expansion story, but the October 26 labor action creates a nearer-term execution test. Investors will be watching whether negotiations protect production continuity while Plant 5 moves toward commercial contribution.

Samsung Biologics faces an October test

The KOSPI-listed company enters October with a KRW 93.50 billion contract, KRW 1,320.90 billion in second-quarter revenue and a planned three-week strike beginning October 26, 2026. The balance between capacity expansion and production stability is now central to the stock narrative.